These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38341388)

  • 41. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
    Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
    Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
    Regnstrom J; Koenig F; Aronsson B; Reimer T; Svendsen K; Tsigkos S; Flamion B; Eichler HG; Vamvakas S
    Eur J Clin Pharmacol; 2010 Jan; 66(1):39-48. PubMed ID: 19936724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
    Lau C; Jamali F; Loebenberg R
    J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
    Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.
    Xu F; Wang Y; Zhu X
    Clin Ther; 2024 Mar; 46(3):267-274. PubMed ID: 38307725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abaloparatide and the Spine: A Narrative Review.
    Thompson JC; Wanderman N; Anderson PA; Freedman BA
    Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
    Miller PD; Troy S; Weiss RJ; Annett M; Schense J; Williams SA; Mitlak B
    Clin Drug Investig; 2021 Mar; 41(3):277-285. PubMed ID: 33638863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications.
    Carvalho M; Martins AP; Sepodes B
    Drug Discov Today; 2019 Mar; 24(3):823-828. PubMed ID: 30579785
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases.
    Alipour-Haris G; Liu X; Acha V; Winterstein AG; Burcu M
    Clin Transl Sci; 2024 Aug; 17(8):e13903. PubMed ID: 39092896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.
    Rohr UP; Iovino M; Rudofsky L; Li Q; Juritz S; Gircys A; Wildner O; Bujar M; Bolte C; Dalla Torre di Sanguinetto S; Wolfer A
    Clin Transl Sci; 2023 Sep; 16(9):1569-1581. PubMed ID: 37408165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abaloparatide: A review of preclinical and clinical studies.
    Brent MB
    Eur J Pharmacol; 2021 Oct; 909():174409. PubMed ID: 34364879
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424.
    Drugs R D; 2008; 9(3):191-6. PubMed ID: 18457472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.